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Abstract: Two interferences recently brought to the fore-
front as patient safety issues include hemolysis (hemo-
globin) and biotin (vitamin B7). The International 
Federation for Clinical Chemistry Committee on Cardiac 
Biomarkers (IFCC-CB) obtained input from a majority of 
cTn and NP assay manufacturers to collate information 
related to high-sensitivity (hs)-cTnI, hs-cTnT, contempo-
rary, and POC cTn assays, and NP assays interferences 
due to hemolysis and biotin. The information contained 
in these tables was designed as educational tools to aid 
laboratory professionals and clinicians in troubleshooting 
cardiac biomarker analytical results that are discordant 
with the clinical situation.
Keywords: biotin; hemolysis; interferences; natriuretic 
peptide; troponin.
Cardiac troponin I and T (cTnI, cTnT) and the natriuretic 
peptides (NP; B-type natriuretic peptide, BNP; N Terminal-
proBNP; NT-proBNP) are the primary cardiac biomarkers 
utilized in the diagnosis of myocardial injury and infarc-
tion (MI) and heart failure (HF), respectively. As with any 
clinical laboratory test, there are exogenous and endog-
enous factors that adversely interfere with the analytical 
performance of the cTn and NP assays, potentially result-
ing in inappropriate clinical interpretation of the results 
if the interferences are not identified. Analytical inter-
ferences are particularly concerning when dealing with 
cardiac biomarker assays, which are utilized to make time 
sensitive critical clinical decisions. Two interferences 
recently brought to the forefront as patient safety issues 
include hemolysis (hemoglobin) and biotin (vitamin B7, 
vitamin H, coenzyme R). The International Federation 
for Clinical Chemistry Committee on Cardiac Biomark-
ers (IFCC-CB) obtained input from a majority of cTn and 
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NP assay manufacturers to collate information related to 
high-sensitivity (hs)-cTnI, hs-cTnT, contemporary, and 
POC cTn assays (Table 1) [1], and NP assays (Table 2) [2] 
interferences due to hemolysis and biotin. The informa-
tion contained in these tables was designed as educa-
tional tools to aid laboratory professionals and clinicians 
in troubleshooting cardiac biomarker analytical results 
that are discordant with the clinical situation.
Hemolysis is one of the major causes of pre-analytical 
errors, reportedly accounting for 40%–70% of all speci-
men rejections [3]. Furthermore, a substantial volume of 
hemolyzed samples occur from specimens collected in the 
emergency department and from indwelling catheters in 
many intensive care units [4]. The accuracy of cTn results 
is of significant importance because it is heavily relied 
upon for making appropriate and rapid patient care deci-
sions. If hemolysis thresholds are exceeded, the specimen 
needs to be recollected, resulting in delays in patient care 
and an increased risk of iatrogenic injury, infection, and 
adverse clinical management in the absence of objective 
information. Hemolysis is a known confounder of hs-cTn 
and cTn assays, causing false positive or false negative 
results; either situation may hinder interpretation of 
single or serial values [5]. Detection of hemolyzed samples 
occurs either manually (visual, qualitative assessment) or 
through automated detection (quantitative or semi-quan-
titative assessment) using indices on the clinical chemistry 
platform. The latter approach is supported as a benchmark 
of good laboratory practice due to the improved reliability, 
accuracy and standardized approach to reporting results 
within a laboratory when using automated mechanisms 
to assess hemolysis. For cTn assays with a low threshold 
for hemolysis (>100 mg/dL, i.e. >1 g/L) the reported rate 
of incorrectly released results is as high as 76% [6]. Not 
all immunoassay platforms or point-of-care devices have 
the ability to routinely perform automated hemolysis 
detection, presenting potential patient safety issues for 
reporting accurate cTn and NP results due to the subjec-
tive nature of visual detection of hemoglobin. Moreover, 
hemolysis will be missed if whole blood is used as the 
matrix for measurements.
Biotin interference is a relatively new challenge 
to laboratories and highlighted by the Food and Drug 
Administration (FDA) warning statement to clinical labo-
ratories (https://www.fda.gov/Safety/MedWatch/Safe-
tyInformation/SafetyAlertsforHumanMedicalProducts/
ucm586641.htm). Investigation of potential interferences 
from biotin in immunoassays is similar to methods uti-
lized for decades in clinical laboratories to probe analyti-
cal interferences. Biotin is a water-soluble vitamin with 
a half-life ranging from 8 to 16  h, depending on renal 
function [7]. Adequate intake is defined at 0.03  mg/day, 
although consumption has expanded and retail sales of 
over-the-counter “mega” doses (2.5–10 mg) of biotin have 
increased significantly due to marketing efforts claiming 
healthier and stronger hair, skin and nails. Furthermore, 
individuals are often unaware that the supplements they 
are ingesting even contain biotin. There are ongoing ran-
domized clinical trials in the US and Europe to evaluate 
biotin doses of 300  mg/day in patients with multiple 
sclerosis and other inflammatory diseases, resulting in 
circulating serum biotin concentrations between 170 and 
700 μg/L [8]. Immunoassays comprised of biotin labeled 
antibodies or biotin-streptavidin labeled complexes are 
particularly susceptible to interferences for a wide array 
of clinical tests.
Data obtained from manufacturers regarding the 
analytical specificity and interference for the cTn and 
NP assays/platforms are presented in Tables 1 and 2, 
respectively. Interference thresholds were defined as 
the greatest concentration for either hemoglobin or 
biotin that did not compromise accuracy of the cTn or 
NP analytical results. When this threshold was exceeded 
results were classified as either falsely high or low, 
allowing laboratory professionals to ascertain the per-
formance of their specific assay/platform in the scenario 
of gross hemolysis or potentially excessive endogenous 
biotin intake. Manufacturers defined their acceptance 
criteria when evaluating and validating interference 
thresholds. The “End User Assessment of Hemolysis” 
column in Tables 1 and 2 was designed to aid clinical 
laboratory personnel performing cardiac biomarker 
testing. If laboratory personnel must visually assess for 
hemolysis before reporting or releasing cTn results the 
assay was designated as “Qualitative”. If the instrument 
automatically assesses for hemolysis to allow erroneous 
results to be suppressed and alerting the laboratorian 
the threshold was exceeded, the assay was designated 
as “Quantitative”.
Biotin interference data in the tables state whether 
a biotinylated antibody is incorporated and/or if biotin 
is used in the assay configuration; it is notable that 
those assays with either characteristic are more suscep-
tible to interference from endogenous biotin use. If high 
dose biotin supplementation is known or suspected due 
to results that do not correlate with the patient’s clini-
cal condition, one possible mitigation strategy could 
involve analysis with another assay that is not suscep-
tible to biotin interference. However, this is not always 
a practical solution and may be problematic due to the 
lack of standardization of cTn and NP assays. Other pro-
posed strategies include adsorption of excess biotin 
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using streptavidin-coated microparticles [8, 9], although 
this requires additional validation within the laboratory 
before implementation.
Cardiac biomarker assays, like a majority of clini-
cal laboratory assays, are susceptible to endogenous 
and exogenous interferences to some extent, which may 
yield analytically incorrect results. There is particular 
concern about the effect of interferences with hs-cTn and 
NP assays, as these are widely used clinically in urgent 
care settings to guide critical clinical decisions but there 
is often less time to carefully consider potential analyti-
cal issues in this situation. For cTn assays, the analytical 
sensitivity and imprecision at the 99th percentile are of 
utmost importance and the consequences of false nega-
tive or false positive results at or near the 99th percentile 
due to hemolysis and/or biotin consumption have been 
highlighted in recent publications [10]. While diagno-
sis of acute MI, ischemia or heart failure should always 
be taken in conjunction with the clinical context of the 
patient, heightened awareness of these analytical issues 
and solutions should be implemented to avoid adverse 
events.
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